openPR Logo
Press release

Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026

05-20-2022 02:44 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global EZH2 Inhibitor Market Opportunity, Sales and Clinical

"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights:

* Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026
* Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug
* Dosage, Price and Sales Analysis of Tazverik
* Tazverik Sales Opportunity > US$ 900 Million by 2026
* Tazverik Sales Forecast 2021 Till 2026
* EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase
* EZH2 Inhibitor in Clinical Trials: 7 Drugs

Download Report:

The advent of next generation sequencing has led to identification of multiple novel molecular alterations in cancer. Since the identification of DNA methylation and histone modification, it has now become evident that genes encoding epigenetic modifiers that locally and globally regulate gene expression play a crucial role in normal development and cancer progression. The field of cancer epigenetics has recently gained considerable interest due to role of epigenetic genes in progression of cancer as well as increasing ability to target these genes. In recent times, the histone methyltransferase enhancer of zeste homolog 2 (EZH2), which is enzymatic catalytic subunit of polycomb repressive complex 2 has emerged as a potential therapeutic target.

"EZH2 Inhibitors Market Opportunity Is Expected to surpass USD 1 billion By 2026 From USD 11 million In 2020"

Tazemetostat (Tazverik) is an EZH2 inhibitor which has recently gained approval by US FDA. The drug Tazverik is developed by Epizyme Inc. and is indicated to treat patients 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Apart from this, the drug is also approved for the management of adult patients with relapsed or refractory follicular lymphoma, who have no satisfactory alternate options. Currently, the drug has been approved in US and Japan and has received orphan designation in Europe. Moreover, the clinical trials with the drug have demonstrated encouraging overall survival rate and positive response rate.

The accelerated approval of Tazemetostat in the management of cancer is thought to revolutionize the overall paradigm of cancer treatment. The global Tazemetostat market was valued around US$ 11.4 Million in 2020 and is expected to witness absolute growth of more than 8000% by 2026. This is mainly due to the robust sales of the drug in short span of time as well as high adoption rates in US market. The integration of EZH2 drug in other therapeutic conditions such as prostate cancer, ovarian cancers and other solid tumors will also aid in boosting the future growth trajectory of the market. Apart from this, it is expected that the drug will gain approval in other regions which will further propel the growth of market.

In coming years, the global market will witness increase in prevalence of cancer attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity and poor diet. This will increase the demand of targeted therapies, thus driving the global EZH2 inhibitor drug market. In addition to Tazemetostat, several pharmaceutical companies have developed potential EZH2 inhibitors candidates including GSK126, CPI1205, SHR2554 and others which are present in clinical stage of development and are expected to gain approval during the forecast period.

As per "Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" report findings, the global EZH2 inhibitor drug market will grow with a CAGR of more than 110% and is expected to surpass US$ 1 Billion by 2026. The high growth rates in the market can be justified by the extensive research and development in this sector and the high adoption rates of approved drug. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. US is expected to dominate the global EZH2 inhibitor drug market due to high adoption rates, increasing research and development activities as well as increase in prevalence of cancer.


Neeraj Chawla
Research Head
Kuick Research

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026 here

News-ID: 2631519 • Views: 483

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight
Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026
"Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026" Report highlights: * Europe Biosimilars Market Opportunity: > USD 10 Billion * Dosage and Pricing insight On Approved Biosimilars * Biosimilars for Cancers Accounts for > 20% Market * Biosimilars for Diabetes Accounts for > 5% Market * Biosimilars Approval and Commercialization by Country * Insight On Biosimilar Clinical Trials By Company, Indication and Phase: > 100 Biosimilars * Insight On Commercially available Biosimilars in Market:

All 5 Releases

More Releases for EZH2

EZH2 Inhibitor Market Witnesses Enormous Opportunities with Daiichi Sankyo, Epiz …
EZH2 Inhibitor Market is projected to hit at $1 Bn by the time duration of 2021-28. EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is upregulated in multiple cancers including, but not limited to, breast, prostate, melanoma, and bladder cancer. EZH2 expression in both cancer cells and immune cells have effects on cancer immunity. EZH2 expression
Recombinant Protein Market continues to expand with Biosimilars Applications
Recombinant proteins have immense potential in cancer therapy research and development. For instance, growth factors, immune checkpoint, and cell damage & oxidative stress proteins (preclinical stage) are utilized from recombinant proteins category for cancer therapy research. Increased understanding of oncogenic signaling pathways and proteins involved in the same has increased the targeting ways, wherein, recombinant proteins such as immune checkpoint, growth factors, and antibodies are used. These proteins are used
Follicular Lymphoma Treatment Market Regional Industry Segmentation Analysis By …
Precision Business Insights published a research report on "Follicular Lymphoma Treatment Market: By Treatment Type (Chemotherapy, Targeted Therapy, Radiotherapy, Monoclonal Antibodies, Stem Cell Transplantation), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Oncology Centers, Academic Research Institutes) and Geography- Global/Region/Country Forecast to 2027" Follicular lymphoma treatment market is anticipated to grow at significant rate during the forecast period 2021-2027. Glance our 200 slides market research and competitive intelligence research
Boost Demand For Recombinant Proteins For Research Purposes | Crown Bioscience, …
Availability of wide number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, and increasing demand for biopharmaceutical products is expected to fuel growth of the recombinant protein market. Manufacturers are involved in collaborations and acquisitions for drug discovery and development purposes. For instance, in 2017, Crown Bioscience (CBI), Inc. entered into collaboration with Jiangsu Qyun Bio-Pharmaceutical Co.
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or …
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The latest report Histone Lysine N Methyltransferase EZH2 Pipeline Review, H1 2017, outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2
Non-Hodgkin Lymphoma Innovative Licensing Industry Opportunities Key Trends, Siz …
Researchmoz added Most up-to-date research on "Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma" to its huge collection of research reports. Non-Hodgkin Lymphoma (NHL) can be seen as a collection of up to 60 smaller subtypes of malignant lymphoid disease, defined by distinct morphological, cytogenetic and immunophenotypic characteristics that can be broadly classified as either indolent or aggressive disease. The slow growing nature of the former means that first-line treatment for